Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Advances in™ ALK+ NSCLC: Leveraging Evidence and Patient Characteristics to Inform Treatment

Release Date: November 15, 2021
Expiration Date: November 15, 2022

Activity Overview

This online activity is designed to provide expert interpretation of new and emerging data on the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC), with a forward-looking perspective on how novel agents may impact clinical practice. The essentials of molecular testing, treatment sequencing, emerging agents, and the management of treatment-related toxicities for ALK-rearranged disease will be presented in a multimedia format. A series of video interviews with an expert thought leader is integrated into text-based elements to provide clinical perspectives.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and pulmonologists interested in the treatment of non–small cell lung cancer (NSCLC). Other allied health care professionals, including pathologists, histologists, nurse practitioners, physician assistants, nurses, and others involved in the treatment and management of patients with ALK-rearranged NSCLC are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine optimal testing strategies and impact on decision making in the front line and subsequent therapeutic management of patients with advanced ALK-positive NSCLC
  • Evaluate emerging clinical trial evidence examining the role of ALK-targeted therapies in the management of first- and later-line therapy in NSCLC
  • Describe treatment sequencing strategies and care planning for patients with advanced ALK-positive NSCLC to address treatment resistance and manage brain metastases
  • Outline preemptive mitigation and management strategies for adverse events associated with ALK inhibitors in multiple lines of care among patients with advanced NSCLC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.


D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Joyce Zeff Chair in Lung Cancer Research
Director of Thoracic Oncology
University of Colorado
Aurora, CO

Disclosures: Advisory role: Ad hoc advisory boards/consultations: AbbVie, Amgen, AnHeart Therapeutics, Apollomics (SRC), AstraZeneca (SRC/SC), Beigene (DSMC), Bio-Thera Solutions (DSMB), Blueprint Medicines, Daiichi-Sankyo (ILD adjudication committee), Elevation Oncology (SRC), Eli Lilly (DSMB and NCCN), EMD Serono, Helsinn (DSMB), Janssen, Kestrel LifeSciences (SAB, Shares), Mersana Therapeutics, Nuvalent (SAB), Puma (NCCN), Ribon Therapeutics, Roche/Genentech, Sanofi, Seattle Genetics, Takeda, Turning Point. Research funding: Inivata. Company sponsored trials at institution (PI roles): AbbVie, AstraZeneca, Dizal Pharma, Inhibrx, Karyopharm, Pfizer, Phosplatin Therapeutics, PsiOxus Therapeutics, Rain Therapeutics, Roche/Genentech, Seattle Genetics, Takeda, Turning Point.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By